Literature DB >> 31485845

Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections.

Mustafa Çakan1, Nuray Aktay Ayaz2, Gonca Keskindemirci3, Şerife Gül Karadağ2, Ayşe Tanatar2, Hafize Emine Sönmez2.   

Abstract

OBJECTIVE: To determine the capability of serum amyloid A (SAA) in differentiating attacks of familial Mediterranean fever (FMF) from acute febrile upper respiratory tract infections.
METHOD: Children diagnosed with FMF during febrile attacks were recorded as the patient group. The control group consisted of children with febrile upper respiratory tract infections. Complete blood count, serum amyloid A (SAA), C-reactive protein (CRP), and erythrocyte sedimentation rate were recorded in both groups during febrile episodes.
RESULTS: The cohort consisted of 28 children with FMF attack and 28 previously healthy children with acute febrile infection. While CRP and SAA levels were elevated in both groups, elevations during FMF attacks were significantly higher in the FMF group than in the control group. Median CRP was 85 mg/L in the FMF attack group and was 36 mg/L in the control group (p = 0.001). Median SAA was 497.5 mg/L in the FMF attack group and was 131.5 mg/L in the control group (p < 0.001). Correlation analyses showed that SAA and CRP were positively correlated in the FMF attack group (r = 0.446, p = 0.01). The best cut-off value for SAA in differentiating FMF attack from an acute febrile infection was 111.5 mg/L (sensitivity 100%, specificity 65.1%, area under curve (AUC) = 0.78, confidence interval 0.66-0.90, p < 0.001).
CONCLUSION: Serum amyloid A is a sensitive but not specific marker for demonstrating inflammation in FMF. SAA levels rise substantially in febrile upper respiratory tract infections.Key Points• SAA levels rise substantially in febrile upper respiratory tract infections.• SAA is a sensitive but not specific method for demonstrating inflammation.• SAA cut-off value for discriminating FMF attacks from febrile infection is 111.5 mg/L (sensitivity 100%, specificity 65.1%).

Entities:  

Keywords:  Acute phase reactants; Familial Mediterranean fever; Infection; Serum amyloid A

Mesh:

Substances:

Year:  2019        PMID: 31485845     DOI: 10.1007/s10067-019-04765-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

Review 1.  An Update on Autoinflammatory Diseases: Inflammasomopathies.

Authors:  Cassandra R Harapas; Annemarie Steiner; Sophia Davidson; Seth L Masters
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

2.  The value of procalcitonin measurements in children with familial Mediterranean fever.

Authors:  Selçuk Yüksel; Mesiha Ekim; Z Birsin Ozçakar; Fatoş Yalçınkaya; Banu Acar; Derya Oztuna; Nejat Akar
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

Review 3.  What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review.

Authors:  Burak Erer; Erkan Demirkaya; Seza Ozen; Tilmann Kallinich
Journal:  Rheumatol Int       Date:  2015-12-28       Impact factor: 2.631

4.  The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study.

Authors:  F Yalçinkaya; N Cakar; B Acar; E Tutar; H Güriz; A H Elhan; S Oztürk; A Kansu; E Ince; S Atalay; N Girgin; U Doğru; D Aysev; M Ekim
Journal:  Rheumatol Int       Date:  2006-11-14       Impact factor: 2.631

5.  Acute phase response in familial Mediterranean fever.

Authors:  C Korkmaz; H Ozdogan; O Kasapçopur; H Yazici
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

Review 6.  Secondary, AA, Amyloidosis.

Authors:  Riccardo Papa; Helen J Lachmann
Journal:  Rheum Dis Clin North Am       Date:  2018-09-07       Impact factor: 2.670

7.  Correlations between serum amyloid A protein and C-reactive protein in infectious diseases.

Authors:  A Lannergård; A Larsson; P Kragsbjerg; G Friman
Journal:  Scand J Clin Lab Invest       Date:  2003       Impact factor: 1.713

8.  A new set of criteria for the diagnosis of familial Mediterranean fever in childhood.

Authors:  Fatos Yalçinkaya; Seza Ozen; Zeynep Birsin Ozçakar; Nuray Aktay; Nilgün Cakar; Ali Düzova; Ozgür Kasapçopur; Atilla H Elhan; Beyza Doganay; Mesiha Ekim; Nazli Kara; Nermin Uncu; Aysin Bakkaloglu
Journal:  Rheumatology (Oxford)       Date:  2009-02-04       Impact factor: 7.580

9.  Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations.

Authors:  H J Lachmann; B Sengül; T U Yavuzşen; D R Booth; S E Booth; A Bybee; J R Gallimore; M Soytürk; S Akar; M Tunca; P N Hawkins
Journal:  Rheumatology (Oxford)       Date:  2006-01-10       Impact factor: 7.580

10.  Lack of the Association of the PTPN22 C1858T Gene Polymorphism With Susceptibility to Familial Mediterranean Fever.

Authors:  Orhan Küçükşahin; Zeynep Şeker; Ali Şahin; Gülay Kinikli; Timur Tuncali; Murat Turgay; Alexis K Okoh; Emre Külahçioğlu; Şükran Erten; Aşkın Ateş
Journal:  Arch Rheumatol       Date:  2016-04-13       Impact factor: 1.472

View more
  2 in total

Review 1.  Neuroinflammation Associated With Inborn Errors of Immunity.

Authors:  Hannes Lindahl; Yenan T Bryceson
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

2.  Evaluation of serum CXC chemokine ligand 16 (CXCL16) as a novel inflammatory bio- marker or familial Mediterranean fever disease

Authors:  Taner Akyol; Tolga Düzenli; Alpaslan Tanoğlu
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.